Expedited Investigational New Drug Pilot Program; Request for Information; Correction

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2026-N-4699] Expedited Investigational New Drug Pilot Program; Request for Information; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 24, 2026. That notice opened a public docket to solicit input and comments on a proposal to establish a pilot program, the Expedited Investigational New Drug pilot program, to shorten the time it takes from drug identification to first-in-human study, while protecting clinical trial participants. FDA is correcting the email address of the document. FOR FURTHER INFORMATION CONTACT: Benjamin Cook, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 2, Rm. 2114, Silver Spring, MD 20993-0002, 240-338-4685, ExpeditedINDPilot@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In the Federal Register of Wednesday, June 24, 2026 (91 FR 37996), in FR Doc. 2026-12621, the following correction is made: On page 37997, in the third column, in the FOR FURTHER INFORMATION CONTACT section, the email is corrected to ExpeditedINDPilot@fda.hhs.gov. Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs. [FR Doc. 2026-13592 Filed 7-2-26; 8:45 am] BILLING CODE 4164-01-P